Experimental cancer drug could help millions of women with osteoporosis and midlife weight gain

Researchers at the University of East Anglia have discovered that an experimental cancer drug may offer a dual benefit for postmenopausal women: protecting against osteoporosis while reducing body fat. Published in npj Drug Discovery, the study reveals that this compound could reverse some metabolic changes associated with menopause. The findings could provide millions of women with a single treatment addressing two major health concerns that typically emerge after menopause. This innovative approach repurposes an existing cancer therapy to tackle conditions that significantly impact women's quality of life and long-term health outcomes.